Tarsus Pharma COO Neervannan Seshadri sells $641k in stock
#Tarsus Pharmaceuticals #Neervannan Seshadri #Insider Trading #NASDAQ:TARS #Rule 10b5-1 #XDEMVY #Stock Sale
📌 Key Takeaways
- Tarsus Pharma COO Neervannan Seshadri sold $641k in company stock under a pre-arranged trading plan
- The stock has gained 72% over the past year and currently trades near $74.90
- Tarsus Pharmaceuticals reported $451.4 million in full-year product sales for 2025
- Analysts consider the stock undervalued relative to its Fair Value
📖 Full Retelling
Tarsus Pharmaceuticals Chief Operating Officer Neervannan Seshadri sold 8,366 shares of company stock on March 4, 2026, at $76.67 per share, totaling $641,421, as part of a pre-arranged trading plan while the company's stock trades near $74.90 following a 72% gain over the past year. The transaction represents a routine sale by an executive utilizing a Rule 10b5-1 trading plan adopted on November 13, 2025, which is designed to prevent insider trading by scheduling trades in advance without access to non-public information. Following the sale, Seshadri maintains a significant stake in the company, directly owning 70,817 shares and indirectly holding 475 shares through his daughter.
Tarsus Pharmaceuticals (NASDAQ:TARS) has been experiencing remarkable growth, with its stock performing exceptionally well despite the recent insider sale. The company recently reported impressive financial results for the fourth quarter of 2025, achieving net product sales of $151.7 million for the quarter and $451.4 million for the full year, primarily driven by its flagship product XDEMVY. Despite these positive financial figures and continued stock appreciation, the company's shares experienced a minor decline in aftermarket trading, suggesting some profit-taking by investors.
According to InvestingPro analysis, Tarsus Pharmaceuticals' stock remains undervalued relative to its Fair Value, placing it among opportunities on the Most Undervalued list. This assessment comes at a pivotal period for the company as it demonstrates strong financial health and market position. The combination of solid financial performance, continued product innovation, and what analysts consider an undervalued stock position presents an interesting scenario for investors monitoring both the company's fundamentals and insider trading activities.
🏷️ Themes
Insider Trading, Pharmaceutical Industry, Stock Market Performance, Corporate Financials
📚 Related People & Topics
Insider trading
Trading using nonpublic information
# Insider Trading **Insider trading** is the trading of a public company's stock or other securities (such as bonds or stock options) based on **material, nonpublic information** about the company. While the practice is common, its legality is subject to complex regulations that vary significantly ...
Entity Intersection Graph
Connections for Insider trading:
🌐
SEC filing
17 shared
🌐
Restricted stock
4 shared
👤
New York Stock Exchange
3 shared
🌐
EVP
3 shared
🌐
Vice president
3 shared
Mentioned Entities
Original Source
try{ var _=i o; . if(!_||_&&typeof _==="object"&&_.expiry Oil prices dip after 5-day winning streak; set for weekly surge on Iran conflict Trump replaces Homeland Security chief Kristi Noem Wall Street ends lower on escalating Iran conflict, report of AI export curbs Trump says he must be involved in selecting Iran’s next leader (South Africa Philippines Nigeria) Tarsus Pharma COO Neervannan Seshadri sells $641k in stock By Insider Trading Published 03/05/2026, 11:34 PM Tarsus Pharma COO Neervannan Seshadri sells $641k in stock 0 TARS -1.71% Tarsus Pharmaceuticals (NASDAQ:TARS) Chief Operating Officer Neervannan Seshadri sold 8,366 shares of common stock on March 4, 2026, at a price of $76.67, for a total transaction value of $641,421. The sale comes as the stock trades near $74.90, following a strong 72% gain over the past year, according to InvestingPro data. Following the transaction, Seshadri directly owns 70,817 shares of Tarsus Pharmaceuticals. The COO also indirectly owns 475 shares through his daughter. The sale was executed under a pre-arranged Rule 10b5-1 trading plan adopted on November 13, 2025. InvestingPro analysis suggests the stock remains undervalued relative to its Fair Value, placing it among opportunities on the Most Undervalued list. For deeper insights, investors can access the comprehensive Pro Research Report, available for TARS and 1,400+ US equities. In other recent news, Tarsus Pharmaceuticals Inc. reported strong financial results for the fourth quarter of 2025, highlighting a significant increase in revenue and profitability. The company achieved net product sales of $151.7 million for the quarter and $451.4 million for the full year. This growth was primarily driven by its flagship product, XDEMVY. Despite these impressive figures, the stock experienced a minor decline in aftermarket trading. The company’s performance reflects a pivotal period of growth. Analyst firms have not provided updates regarding upgrades or downgrades in the pro...
Read full article at source